Shivaani Kummar

基本信息

Career Trajectory

Bio

Dr. Kummar is a cancer specialist whose focus is to bring new discoveries to the clinic, developing new treatments for cancer. She runs early phase clinical trials evaluating new treatments while ensuring highest standards of patient safety.

Research Interests

Papers共 460 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Myeloid Targeting Antibodies PY159 and PY314 for Platinum-Resistant Ovarian Cancer

Oladapo O Yeku,Minal Barve, Winston W Tan, Judy Wang,Amita Patnaik,Patricia LoRusso,Debra L Richardson,Abdul Rafeh Naqash, Sarah K Lynam,Siqing Fu,Michael Gordon,Joleen Hubbard,Shivaani Kummar,Christos Kyriakopoulos,Afshin Dowlati, Marc Chamberlain,Ira Winer

Journal for immunotherapy of cancerno. 3 (2025)

Cited0Views0WOSBibtex

Nirogacestat-the Pathway to Approval of the First Treatment for Desmoid Tumors, a Rare Disease

Shivaani Kummar,Nam Bui,Wells A Messersmith, Jeanne Whiting,Marlene Portnoy,Allison Lim, L Mary

Therapeutic advances in rare disease (2025): 26330040251317546-26330040251317546

Cited0Views0WOSBibtex

Table 2 from First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies

Shivaani Kummar,Albiruni Abdul Razak, Scott Laurie,Dylan M. Glatt,Sariah Kell, Anh N. Diep,Maike Schmidt, Clifford Hom, Chris German, Suyash S. Shringarpure,Sophia R. Majeed,Drew Rasco

crossref（2025）

Cited0Views0Bibtex

A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors

Sarah J Shin,Geraldine O'Sullivan Coyne,Shivaani Kummar,Sarah B Miller, Barry C Johnson, Larry Anderson,Larry Rubinstein,Brandon Miller,Deborah F Wilsker,Katherine V Ferry-Galow,Richard Piekarz,Jennifer Zlott, Murielle Hogu,Lamin Juwara,Julia Krushkal, Mariam Konaté,Alida Palmisano,Yingdong Zhao, Jerry Collins,Ralph E Parchment,James H Doroshow,Alice P Chen

Clinical cancer research an official journal of the American Association for Cancer Researchno. 11 (2025): 2124-2133

Cited0Views0WOSBibtex

Figure S2 from First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies

Shivaani Kummar,Albiruni Abdul Razak, Scott Laurie,Dylan M. Glatt,Sariah Kell, Anh N. Diep,Maike Schmidt, Clifford Hom, Chris German, Suyash S. Shringarpure,Sophia R. Majeed,Drew Rasco

crossref（2025）

Cited0Views0Bibtex

A Study to Learn if Nirogacestat Works and is Safe for Adult Participants with Desmoid Tumors: a Plain Language Summary of the DeFi Study

Bernd Kasper, Jeanne Whiting, Dana Lawson,Marlene Portnoy,Kathrin Schuster, Christina Baumgarten,Ravin Ratan, Allison Lim, Sunny Cho,Shivaani Kummar, Mrinal Gounder

Future oncology (London, England)no. 8 (2025): 889-901

Cited0Views0WOSBibtex

Preclinical NCI-MPACT: Prospective Modeling of the Mutation-Based NCI-MPACT Clinical Trial Therapeutic Strategy in Patient-Derived Xenograft Models

Yvonne A Evrard,Sergio Y Alcoser,Michael Mullendore,Li Chen,Chih-Jian Lih, Vishnuprabha Rahul Kannan, Vivekananda Datta, Lindsay Dutko, Shahanawaz Jiwani, Lawrence V Rubinstein,Yingdong Zhao,P Mickey Williams,Alida Palmisano, Laura Kuhlmann,Mel Simpson,Shivaani Kummar,Biswajit Das,Chris Karlovich, Eric Polley,Ming-Chung Li, Alice P Chen,Melinda G Hollingshead, James H Doroshow

Frontiers in oncology (2025): 1571635-1571635

Cited0Views0WOSBibtex

Phase 1/2 Study of FOG-001, a First-in-class Direct Β-Catenin:Tcf Inhibitor, in Patients with Colorectal Cancer, Hepatocellular Carcinoma, and Other Locally Advanced or Metastatic Solid Tumors

Kyriakos P. Papadopoulos,Michael Cecchini,Moh'd M. Khushman,Meredith Pelster,Jordi Rodon Ahnert,Shivaani Kummar,Rona Yaeger,Sunil Sharma, Amber L. Wells, Amanda Garofalo,Lalith V Akella, Ziyang Yu, Varsha Iyer, Marie Huong Nguyen,Keith W. Orford,Samuel J. Klempner

Journal of Clinical Oncologyno. 4_suppl (2025)

Cited0Views0Bibtex

First-in-human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies

Shivaani Kummar,Albiruni Abdul Razak,Scott Laurie,Dylan M. Glatt,Sariah Kell, Anh N. Diep,Maike Schmidt, Clifford Hom, Chris German, Suyash S. Shringarpure,Sophia R. Majeed,Drew Rasco

CANCER RESEARCH COMMUNICATIONSno. 1 (2025): 94-105

Cited0Views0WOSBibtex

Supplementary Data from First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies

Shivaani Kummar,Albiruni Abdul Razak,Scott Laurie,Dylan M. Glatt,Sariah Kell, Anh N. Diep,Maike Schmidt, Clifford Hom, Chris German, Suyash S. Shringarpure,Sophia R. Majeed,Drew Rasco

crossref（2025）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Research Professor

Papers共 460 篇Author StatisticsCo-AuthorSimilar Experts